IceCure Medical (NASDAQ:ICCM) Stock Rating Reaffirmed by HC Wainwright

IceCure Medical (NASDAQ:ICCMGet Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $3.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 140.00% from the company’s previous close.

Separately, Alliance Global Partners raised their price objective on shares of IceCure Medical from $1.90 to $2.90 and gave the company a “buy” rating in a research report on Wednesday, March 20th.

Check Out Our Latest Stock Report on ICCM

IceCure Medical Price Performance

Shares of NASDAQ:ICCM opened at $1.25 on Thursday. The business has a fifty day simple moving average of $1.30 and a 200 day simple moving average of $1.07. The company has a current ratio of 4.03, a quick ratio of 3.41 and a debt-to-equity ratio of 0.03. IceCure Medical has a 1 year low of $0.52 and a 1 year high of $1.57. The firm has a market cap of $57.03 million, a price-to-earnings ratio of -3.38 and a beta of 0.73.

Hedge Funds Weigh In On IceCure Medical

Institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. bought a new stake in IceCure Medical in the 2nd quarter valued at $78,000. Boothbay Fund Management LLC lifted its stake in shares of IceCure Medical by 100.0% in the fourth quarter. Boothbay Fund Management LLC now owns 40,000 shares of the company’s stock valued at $62,000 after buying an additional 20,000 shares during the period. Bank of America Corp DE lifted its stake in shares of IceCure Medical by 57.2% in the fourth quarter. Bank of America Corp DE now owns 55,388 shares of the company’s stock valued at $86,000 after buying an additional 20,159 shares during the period. Finally, UBS Group AG lifted its stake in shares of IceCure Medical by 1,302.3% in the fourth quarter. UBS Group AG now owns 28,986 shares of the company’s stock valued at $45,000 after buying an additional 26,919 shares during the period. Institutional investors own 0.62% of the company’s stock.

IceCure Medical Company Profile

(Get Free Report)

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.

Featured Stories

Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.